Form 4: Esperion Therapeutics Insider Sells Shares

Sheldon L. Koenig, President and CEO of Esperion Therapeutics, reported a transaction involving the sale of common stock.

Summary

• Sheldon L. Koenig, President and CEO and Director of Esperion Therapeutics, Inc., reported a transaction on June 17, 2026.
• The transaction involved the sale of 53,588 shares of common stock.
• The sale was executed at a price of $3.155 per share.
• The reason for the sale was to satisfy tax obligations related to vested restricted stock units.
• Following this transaction, Mr. Koenig beneficially owns 2,119,111 shares of common stock directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider sale, though the clear explanation for tax purposes mitigates significant concern.

Negatives

• An insider, the President and CEO, sold a significant number of shares (53,588).

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling, particularly by high-ranking executives like a CEO, can sometimes be interpreted negatively by the market, although in this instance, the sale was explicitly for tax obligations related to vested equity.

Stakeholder Impact

• Shareholders may view the CEO's sale of shares with some concern, even though it is for tax obligations, as it reduces insider ownership.

Key Dates

Keywords

Esperion Therapeutics, ESPR, Form 4, Insider Transaction, Stock Sale, Sheldon L. Koenig, Restricted Stock Units, Tax Obligation